83 related articles for article (PubMed ID: 8996242)
1. Interleukin-4 protects against a genetically linked lupus-like autoimmune syndrome.
Santiago ML; Fossati L; Jacquet C; Müller W; Izui S; Reininger L
J Exp Med; 1997 Jan; 185(1):65-70. PubMed ID: 8996242
[TBL] [Abstract][Full Text] [Related]
2. Vitamin D Presented In Vitro Immunomodulatory Property on T Lymphocyte-Related Cytokines in Systemic Lupus Erythematosus.
Mariz HA; Sato EI; Cardoso PRG; Gonçalves R; Duarte ALBP; de Melo Rego MJB; da Rocha Pitta I; da Rocha Pitta MG
Inflammation; 2023 Apr; 46(2):730-738. PubMed ID: 36459355
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of Tumor Necrosis Factor-Alpha Inhibitor-Induced Systemic Lupus Erythematosus.
Yen CY; Yu SJ; Chen YM; Lai KL; Wu YD; Liao EC; Hsieh CL
Front Med (Lausanne); 2022; 9():870724. PubMed ID: 35733860
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-4 Supports the Suppressive Immune Responses Elicited by Regulatory T Cells.
Yang WC; Hwang YS; Chen YY; Liu CL; Shen CN; Hong WH; Lo SM; Shen CR
Front Immunol; 2017; 8():1508. PubMed ID: 29184551
[TBL] [Abstract][Full Text] [Related]
5. IgG3 deficiency extends lifespan and attenuates progression of glomerulonephritis in MRL/lpr mice.
Greenspan NS; Lu MA; Shipley JW; Ding X; Li Q; Sultana D; Kollaros M; Schreiber JR; Fu P; Putterman C; Emancipator SN
Biol Direct; 2012 Jan; 7():3. PubMed ID: 22248284
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic strategies for SLE involving cytokines: mechanism-oriented therapies especially IFN-gamma targeting gene therapy.
Hayashi T
J Biomed Biotechnol; 2010; 2010():. PubMed ID: 20827419
[TBL] [Abstract][Full Text] [Related]
7. B cells require "nurturing" by CD4 T cells during development in order to respond in chronic graft-versus-host model of systemic lupus erythematosus.
Choudhury A; Cohen PL; Eisenberg RA
Clin Immunol; 2010 Jul; 136(1):105-15. PubMed ID: 20381429
[TBL] [Abstract][Full Text] [Related]
8. Treatment with a toll-like receptor inhibitory GpG oligonucleotide delays and attenuates lupus nephritis in NZB/W mice.
Graham KL; Lee LY; Higgins JP; Steinman L; Utz PJ; Ho PP
Autoimmunity; 2010 Mar; 43(2):140-55. PubMed ID: 19845477
[TBL] [Abstract][Full Text] [Related]
9. A role for sex chromosome complement in the female bias in autoimmune disease.
Smith-Bouvier DL; Divekar AA; Sasidhar M; Du S; Tiwari-Woodruff SK; King JK; Arnold AP; Singh RR; Voskuhl RR
J Exp Med; 2008 May; 205(5):1099-108. PubMed ID: 18443225
[TBL] [Abstract][Full Text] [Related]
10. Role of T cells and dendritic cells in glomerular immunopathology.
Kurts C; Heymann F; Lukacs-Kornek V; Boor P; Floege J
Semin Immunopathol; 2007 Nov; 29(4):317-35. PubMed ID: 17955242
[TBL] [Abstract][Full Text] [Related]
11. Examining the role of CD1d and natural killer T cells in the development of nephritis in a genetically susceptible lupus model.
Yang JQ; Wen X; Liu H; Folayan G; Dong X; Zhou M; Van Kaer L; Singh RR
Arthritis Rheum; 2007 Apr; 56(4):1219-33. PubMed ID: 17393451
[TBL] [Abstract][Full Text] [Related]
12. Molecular and cellular basis for pathogenicity of autoantibodies: lessons from murine monoclonal autoantibodies.
Baudino L; Azeredo da Silveira S; Nakata M; Izui S
Springer Semin Immunopathol; 2006 Oct; 28(2):175-84. PubMed ID: 16953439
[TBL] [Abstract][Full Text] [Related]
13. Simvastatin treatment ameliorates autoimmune disease associated with accelerated atherosclerosis in a murine lupus model.
Aprahamian T; Bonegio R; Rizzo J; Perlman H; Lefer DJ; Rifkin IR; Walsh K
J Immunol; 2006 Sep; 177(5):3028-34. PubMed ID: 16920939
[TBL] [Abstract][Full Text] [Related]
14. Activation of natural killer T cells in NZB/W mice induces Th1-type immune responses exacerbating lupus.
Zeng D; Liu Y; Sidobre S; Kronenberg M; Strober S
J Clin Invest; 2003 Oct; 112(8):1211-22. PubMed ID: 14561706
[TBL] [Abstract][Full Text] [Related]
15. Differential contribution of IL-4 and STAT6 vs STAT4 to the development of lupus nephritis.
Singh RR; Saxena V; Zang S; Li L; Finkelman FD; Witte DP; Jacob CO
J Immunol; 2003 May; 170(9):4818-25. PubMed ID: 12707364
[TBL] [Abstract][Full Text] [Related]
16. Beneficial effects of the anti-oestrogen tamoxifen on systemic lupus erythematosus of (NZBxNZW)F1 female mice are associated with specific reduction of IgG3 autoantibodies.
Sthoeger ZM; Zinger H; Mozes E
Ann Rheum Dis; 2003 Apr; 62(4):341-6. PubMed ID: 12634234
[TBL] [Abstract][Full Text] [Related]
17. Therapy of systemic lupus erythematosus: a look into the future.
Smolen JS
Arthritis Res; 2002; 4 Suppl 3(Suppl 3):S25-30. PubMed ID: 12110120
[TBL] [Abstract][Full Text] [Related]
18. Isotype-dependent pathogenicity of autoantibodies: analysis in experimental autoimmune hemolytic anemia.
Izui S; Fossati-Jimack L; da Silveira SA; Moll T
Springer Semin Immunopathol; 2001 Dec; 23(4):433-45. PubMed ID: 11826619
[No Abstract] [Full Text] [Related]
19. The role of IFN-gamma in systemic lupus erythematosus: a challenge to the Th1/Th2 paradigm in autoimmunity.
Theofilopoulos AN; Koundouris S; Kono DH; Lawson BR
Arthritis Res; 2001; 3(3):136-41. PubMed ID: 11299053
[TBL] [Abstract][Full Text] [Related]
20. Markedly different pathogenicity of four immunoglobulin G isotype-switch variants of an antierythrocyte autoantibody is based on their capacity to interact in vivo with the low-affinity Fcgamma receptor III.
Fossati-Jimack L; Ioan-Facsinay A; Reininger L; Chicheportiche Y; Watanabe N; Saito T; Hofhuis FM; Gessner JE; Schiller C; Schmidt RE; Honjo T; Verbeek JS; Izui S
J Exp Med; 2000 Apr; 191(8):1293-302. PubMed ID: 10770797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
